Literature DB >> 24668022

Absence Epilepsy: Older vs Newer AEDs.

Jeffrey R Tenney1, Sejal V Jain.   

Abstract

OPINION STATEMENT: Over the last one to two decades, several new antiepileptic drugs (AEDs) have become available. These medications have different mechanisms of action, metabolism, efficacy, and side effect profiles. Hence, it has become possible to customize medications for a particular patient. It has also become possible to use various combinations of treatments for refractory epilepsies. As medication options have increased, our goal has shifted to not only to maximize seizure control but also to minimize side effects. However, the older AEDs are still widely used. So the question arises-are newer medications better than older AEDs for the treatment of absence epilepsy? Based on a large multicenter class I study, older AEDs-ethosuximide and valproic acid-are more efficacious than newer AEDs. Due to reduced side effects, ethosuximide remains the first line treatment for childhood absence epilepsy.

Entities:  

Year:  2014        PMID: 24668022     DOI: 10.1007/s11940-014-0290-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  61 in total

1.  Long-term follow-up of absence seizures.

Authors:  S Sato; F E Dreifuss; J K Penry; D D Kirby; Y Palesch
Journal:  Neurology       Date:  1983-12       Impact factor: 9.910

2.  Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal).

Authors:  N Callaghan; J O'Hare; D O'Driscoll; B O'Neill; M Daly
Journal:  Dev Med Child Neurol       Date:  1982-12       Impact factor: 5.449

3.  How well can epilepsy syndromes be identified at diagnosis? A reassessment 2 years after initial diagnosis.

Authors:  A T Berg; S Shinnar; S R Levy; F M Testa; S Smith-Rapaport; B Beckerman
Journal:  Epilepsia       Date:  2000-10       Impact factor: 5.864

4.  Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months.

Authors:  Tracy A Glauser; Avital Cnaan; Shlomo Shinnar; Deborah G Hirtz; Dennis Dlugos; David Masur; Peggy O Clark; Peter C Adamson
Journal:  Epilepsia       Date:  2012-11-21       Impact factor: 5.864

5.  A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy.

Authors:  Cinzia Fattore; Clementina Boniver; Giuseppe Capovilla; Caterina Cerminara; Antonietta Citterio; Giangennaro Coppola; Paola Costa; Francesca Darra; Marilena Vecchi; Emilio Perucca
Journal:  Epilepsia       Date:  2011-02-14       Impact factor: 5.864

6.  Epilepsy syndromes in patients with childhood-onset seizures in Finland.

Authors:  M Sillanpää; M Jalava; S Shinnar
Journal:  Pediatr Neurol       Date:  1999-08       Impact factor: 3.372

7.  Absence epilepsy in childhood: electroencephalography (EEG) does not predict outcome.

Authors:  D Barry Sinclair; Hussein Unwala
Journal:  J Child Neurol       Date:  2007-07       Impact factor: 1.987

8.  Long-term prognosis in two forms of childhood epilepsy: typical absence seizures and epilepsy with rolandic (centrotemporal) EEG foci.

Authors:  P Loiseau; M Pestre; J F Dartigues; D Commenges; C Barberger-Gateau; S Cohadon
Journal:  Ann Neurol       Date:  1983-06       Impact factor: 10.422

9.  Childhood absence epilepsy: behavioral, cognitive, and linguistic comorbidities.

Authors:  Rochelle Caplan; Prabha Siddarth; Lesley Stahl; Erin Lanphier; Pamela Vona; Suresh Gurbani; Susan Koh; Raman Sankar; W Donald Shields
Journal:  Epilepsia       Date:  2008-06-13       Impact factor: 5.864

10.  Lamotrigine monotherapy for newly diagnosed typical absence seizures in children.

Authors:  Gregory L Holmes; L Matthew Frank; Raj D Sheth; Bryan Philbrook; John D Wooten; Alain Vuong; Susan Kerls; Anne E Hammer; John Messenheimer
Journal:  Epilepsy Res       Date:  2008-09-07       Impact factor: 3.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.